Look at Whole Prescribing Facts OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed soon after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or after 3 or even more lines of systemic therapy that includes autologous HSCT.If